24 related articles for article (PubMed ID: 38520679)
1. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Kamal HM; Ahmed AS; Fawzy MS; Mohamed FA; Elbaz AA
Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
Fawzy MS; Mohammed EA; Ahmed AS; Fakhr-Eldeen A
Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
[TBL] [Abstract][Full Text] [Related]
3. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
[TBL] [Abstract][Full Text] [Related]
6. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
Shi J; Zhi P; Chen J; Wu P; Tan S
Thromb Res; 2014 Sep; 134(3):610-6. PubMed ID: 25042727
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Qian K; Xu J; Wan H; Fu F; Lu J; Lin Z; Liu Z; Liu H
Gene; 2015 Sep; 569(2):173-81. PubMed ID: 26071134
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
9. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
Toh CH
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
[TBL] [Abstract][Full Text] [Related]
10. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
Urano T
Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
Hamdy M; Shaheen IA; Khallaf M; Selim YMM
Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
